Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

ALDX
Aldeyra Therapeutics, Inc.
stock NASDAQ

At Close
Jul 16, 2026 3:59:57 PM EDT
1.72USD-10.417%(-0.20)2,579,544
1.71Bid   1.97Ask   0.26Spread
Pre-market
Jul 16, 2026 9:29:30 AM EDT
1.80USD-6.250%(-0.12)85,130
After-hours
Jul 16, 2026 4:07:30 PM EDT
1.71USD-0.564%(-0.01)100
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 11, 2022
08:56AM EST  Aldeyra Therapeutics, Inc. (ALDX) announced positive data from a Phase 2 clinical trial comparing ocular discomfort and itching symptom scores of reproxalap ophthalmic solution 0.25%, an investigational new drug, versus Xiidra or lifitegrast ophthalmic solution 5 percent in patients with dry eye disease.   RTTNews
08:11AM EST  Aldeyra Announces Positive Data From Phase 2 Dry Eye Chamber Trial Of Reproxalap Vs. Xiidra   RTTNews
08:06AM EST  Aldeyra Therapeutics Announces Top-Line Data From Phase 2 Dry Eye Chamber Clinical Trial Of Reproxalap; Says Reproxalap Patient-Reported Ocular Discomfort And Itching Were Statistically Lower Than With Xiidra   Benzinga
08:00AM EST  Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra(r)   Business Wire
Jan 6, 2022
08:00AM EST  Aldeyra Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BioConnect Virtual Conference   Business Wire
Jan 4, 2022
08:11AM EST  Aldeyra Therapeutics Reports Completion Of Enrollment In Phase 1 Of Phase 3 GUARD Trial Of ADX-2191 In Proliferative Vitreoretinopathy   Benzinga
08:10AM EST  Aldeyra Completes Enrollment In Part 1 Of Phase 3 Trial of ADX-2191 In Proliferative Vitreoretinopathy   RTTNews
08:00AM EST  Aldeyra Therapeutics Completes Enrollment in Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy   Business Wire
Dec 21, 2021
02:47PM EST  Mid-Afternoon Market Update: Dow Jumps Over 500 Points; Rite Aid Shares Spike Higher   Benzinga
01:03PM EST  Shares of Aldeyra Therapeutics, Inc. (ALDX) tanked over 50% on Tuesday morning after the company said its late-stage trial of dry eye disease treatment failed to meet primary endpoint.   RTTNews
12:33PM EST  Mid-Day Market Update: Crude Oil Rises 3%; Aldeyra Therapeutics Shares Slide   Benzinga
10:12AM EST  Mid-Morning Market Update: Markets Open Higher; General Mills Earnings Miss Views   Benzinga
09:42AM EST  Citigroup Maintains Buy on Aldeyra Therapeutics, Lowers Price Target to $21   Benzinga
08:12AM EST  The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail   Benzinga
07:31AM EST  10 Biggest Price Target Changes For Tuesday   Benzinga
05:25AM EST  SVB Leerink Maintains Outperform on Aldeyra Therapeutics, Lowers Price Target to $15   Benzinga
Dec 20, 2021
04:10PM EST  Aldeyra Therapeutics Announces Top-Line Results From The Phase 3 TRANQUILITY Trial In Dry Eye Disease   RTTNews
04:07PM EST  UPDATE: Aldeyra Sees Dry Eye Disease New Drug Application Submitted In Mid 2022   Benzinga
04:06PM EST  UPDATE: Aldeyra Says Primary Endpoint For TRANQUILITY-2 Trial Modified 'to be Met if Either Ocular Redness or Schirmer Test Achieved; Target Enrollment Increased from 300 to up to 400 Patients; Top-Line Results Expected Mid-2022'   Benzinga
04:06PM EST  Aldeyra Therapeutics Reports Phase 3 TRANQUILITY Trial In Dry Eye Disease Candidate Did Not Meet Primary Endpoint Of Ocular Redness   Benzinga
04:05PM EST  Aldeyra Therapeutics Announces Top-Line Results from the Phase 3 TRANQUILITY Trial in Dry Eye Disease   Business Wire
04:01PM EST  Aldeyra Therapeutics Shares Halted On Code News Pending   Benzinga
Nov 9, 2021
04:06PM EST  Aldeyra Therapeutics to Participate in Upcoming Conferences   Business Wire
11:42AM EST  Aldeyra Therapeutics Announces Completion Of Enrollment In Phase 3 TRANQUILITY Trial In Patients With Dry Eye Disease And Reiterates New Drug Application (NDA) Submission Guidance   Benzinga
08:15AM EST  Aldeyra Therapeutics Completes Enrollment In Phase 3 TRANQUILITY Trial In Patients With Dry Eye Disease   RTTNews
08:00AM EST  Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY Trial in Patients with Dry Eye Disease and Reiterates New Drug Application (NDA) Submission Guidance   Business Wire
Nov 2, 2021
10:54AM EDT  Aldeyra Therapeutics Reports Achieved Primary Endpoint Of Ocular Redness In Phase 2 Trial In Dry Eye Disease   Benzinga
08:29AM EDT  Aldeyra Therapeutics Achieves Primary Endpoint Of Ocular Redness In Phase 2 Clinical Trial In Dry Eye Disease   RTTNews
08:00AM EDT  Aldeyra Therapeutics Announces Achievement of Primary Endpoint of Ocular Redness in Randomized, Double-Masked, Vehicle-Controlled Phase 2 Clinical Trial in Dry Eye Disease   Business Wire
Nov 1, 2021
09:24AM EDT  Aldeyra Therapeutics Sponsored Study Titled 'An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease' Posted To ClinicalTrials.gov; Study Is Recruiting   Benzinga
Oct 28, 2021
08:26AM EDT  The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug   Benzinga
07:41AM EDT  Aldeyra Therapeutics Q3 Net Loss $15.8 Mln Vs Net Loss $8.9 Mln Last Year   RTTNews
07:37AM EDT  Aldeyra Therapeutics Q3 EPS $(0.27) Misses $(0.26) Estimate   Benzinga
07:00AM EDT  Aldeyra Therapeutics Reports Third-Quarter 2021 Financial Results and Recent Corporate Highlights   Business Wire
04:08AM EDT  Earnings Scheduled For October 28, 2021   Benzinga
Oct 21, 2021
08:00AM EDT  Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2021 Financial Results and Discuss Recent Business Highlights   Business Wire
Sep 20, 2021
01:46PM EDT  Aldeyra Therapeutics Option Alert: Dec 17 $10 Calls Sweep (14) near the Ask: 208 @ $1.5 vs 2131 OI; Earnings 11/4 Before Open [est] Ref=$8.02   Benzinga
Sep 9, 2021
08:00AM EDT  Aldeyra Therapeutics to Participate in the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit   Business Wire
Sep 2, 2021
08:00AM EDT  Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences   Business Wire
Aug 5, 2021
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
07:27AM EDT  Aldeyra Therapeutics Q2 EPS $(0.28) Misses $(0.24) Estimate   Benzinga
07:19AM EDT  Aldeyra Therapeutics Q2 Net Loss $14.9 Mln Vs Net Loss $7.5 Mln Last Year   RTTNews
07:00AM EDT  Aldeyra Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Corporate Highlights   Business Wire
04:08AM EDT  Earnings Scheduled For August 5, 2021   Benzinga
Aug 4, 2021
11:23AM EDT  Aldeyra Secures US Orphan Drug Tag For Its Retinitis Pigmentosa Candidate   Benzinga
08:48AM EDT  Aldeyra Therapeutics Earlier Announced Receipt Of Orphan Drug Designation From FDA For ADX-2191 To Treat Retinitis Pigmentosa   Benzinga
08:08AM EDT  Aldeyra Receives Orphan Drug Designation From FDA For ADX-2191 To Treat Retinitis Pigmentosa   RTTNews
08:00AM EDT  Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Retinitis Pigmentosa   Business Wire
Aug 3, 2021
08:00AM EDT  Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences   Business Wire
Aug 1, 2021
11:19AM EDT  The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs   Benzinga
Jul 29, 2021
08:00AM EDT  Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2021 Financial Results and Discuss Recent Business Highlights   Business Wire
Jul 20, 2021
09:19AM EDT  Aldeyra Stock Trading Higher On FDA Orphan Drug Tag For Primary Vitreoretinal Lymphoma Candidate   Benzinga
08:20AM EDT  The U.S. Food and Drug Administration has granted orphan drug designation to Aldeyra Therapeutics Inc. (ALDX) for ADX-2191 or methotrexate for intravitreal injection for the treatment of primary vitreoretinal lymphoma or PVRL.   RTTNews
08:05AM EDT  Aldeyra Therapeutics Says Gets Orphan Drug Designation From US FDA For ADX-2191 To Treat Primary Vitreoretinal Lymphoma   RTTNews
08:00AM EDT  Aldeyra Therapeutics Receives Orphan Drug Designation From FDA For ADX-2191 To Treat Primary Vitreoretinal Lymphoma   Benzinga
08:00AM EDT  Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Primary Vitreoretinal Lymphoma   Business Wire
Jul 19, 2021
11:48AM EDT  Aldeyra Therapeutics FDA AccessData Listing For Co.'s Treatment Candidate For Primary Vitreoretinal Lymphoma Shows Orphan Drug Designation   Benzinga
Jul 1, 2021
08:18AM EDT  Aldeyra Therapeutics Joined Russell 2000, 3000 Indices As Of Jun. 28, 2021   Benzinga
08:00AM EDT  Aldeyra Therapeutics Joins the Russell 2000(r) and Russell 3000(r) Indexes   Business Wire
May 27, 2021
08:00AM EDT  Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference   Business Wire
May 8, 2021
12:10PM EDT  The Past Week's Notable Insider Buys: Amphenol, Aldeyra, Werewolf Therapeutics And More   Benzinga
May 6, 2021
07:59AM EDT  Aldeyra Therapeutics Q1 EPS $(0.25) Beats $(0.27) Estimate   Benzinga
07:49AM EDT  The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom   Benzinga
07:00AM EDT  Aldeyra Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Highlights   Business Wire
04:17AM EDT  Earnings Scheduled For May 6, 2021   Benzinga
May 5, 2021
05:47AM EDT  Perceptive Advisors Reported Purchase of 1.2M Shares of Aldeyra Therapeutics Thursday @ Avg Price of $12.50/Share in a Form 4 Filing on Tuesday   Benzinga
Apr 29, 2021
08:00AM EDT  Aldeyra Therapeutics Schedules Webcast and Conference Call to Report First-Quarter 2021 Financial Results and Discuss Recent Business Highlights   Business Wire
Apr 28, 2021
06:31PM EDT  Aldeyra Therapeutics, Inc. Announces Pricing of $125 Million Public Offering of Common Stock   Business Wire
07:26AM EDT  The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping   Benzinga
06:10AM EDT  Aldeyra Seeks To Raise $125M Via Equity To Support Reproxalap US Application   Benzinga
Apr 27, 2021
04:16PM EDT  Aldeyra Therapeutics, Inc. Announces Proposed $125M Public Offering of Common Stock   Benzinga
04:01PM EDT  Aldeyra Therapeutics, Inc. Announces Proposed $125 Million Public Offering of Common Stock   Business Wire
02:32PM EDT  Mid-Afternoon Market Update: TrueBlue Rises Following Q1 Earnings; RealNetworks Shares Slide   Benzinga
12:16PM EDT  Mid-Day Market Update: Crude Oil Rises 1%; PQ Group Shares Plummet   Benzinga
08:46AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Apr. 27, 2021: UPS, ALDX, FISV, PFPT, GOOG   Benzinga
08:09AM EDT  Aldeyra Therapeutics, Inc. (ALDX) reported positive top-line results from the phase 3 INVIGORATE clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug, in patients with allergic conjunctivitis. The company said the clinical trial successfully achieved statistical significance for the primary endpoint and all secondary endpoints.   RTTNews
07:56AM EDT  Aldeyra Achieves Primary Endpoint And All Secondary Endpoints In Phase 3 Trial Of Reproxalap In Allergic Conjunctivitis   RTTNews
07:41AM EDT  The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout   Benzinga
07:40AM EDT  Aldeyra Therapeutics Stock Is Trading Higher On Acing Allergic Conjunctivitis Study With Reproxalap   Benzinga
07:01AM EDT  Aldeyra Therapeutics Achieves Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE Clinical Trial of Reproxalap in Allergic Conjunctivitis   Benzinga
Apr 26, 2021
04:05PM EDT  Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE Clinical Trial   Business Wire
Mar 12, 2021
06:15AM EST  SVB Leerink Initiates Coverage On Aldeyra Therapeutics with Outperform Rating, Announces Price Target of $22   Benzinga
Mar 11, 2021
08:19AM EST  The Daily Biotech Pulse: Contrasting COVID-19 Treatment Readouts From Roche, Vir, Delay In Kadmon's FDA Review, Alzheimer's Data From Prothena   Benzinga
07:13AM EST  Aldeyra Therapeutics Net Loss For Full-year 2020 $37.6 Mln Or $1.11 Per Share   RTTNews
07:06AM EST  Aldeyra Therapeutics Reports FY20 EPS $(1.11) Up From $(2.24) YoY   Benzinga
07:00AM EST  Aldeyra Therapeutics Reports Full-Year 2020 Financial Results and Recent Business Highlights   Business Wire
03:35AM EST  Earnings Scheduled For March 11, 2021   Benzinga
Mar 10, 2021
08:00AM EST  Aldeyra Therapeutics to Present at the OIS Dry Eye Innovation Showcase on March 11, 2021   Business Wire
Mar 6, 2021
10:58AM EST  The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings   Benzinga
Mar 4, 2021
08:00AM EST  Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2020 Financial Results and Discuss Recent Business Highlights   Business Wire
Mar 2, 2021
08:00AM EST  Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences   Business Wire
Feb 18, 2021
08:00AM EST  Aldeyra Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference   Business Wire
Feb 8, 2021
10:12AM EST  Benzinga's Top Ratings Upgrades, Downgrades For February 8, 2021   Benzinga
06:37AM EST  HC Wainwright & Co. Initiates Coverage On Aldeyra Therapeutics with Buy Rating, Announces Price Target of $26   Benzinga
Feb 4, 2021
08:13AM EST  Aldeyra Therapeutics Announces Phase 3 TRANQUILITY Dry Eye Disease Trial Design; Co. Announces 'TRANQUILITY to Utilize Two-Day Treatment and Challenge Design '   Benzinga
Jan 30, 2021
11:10AM EST  Notable Insider Buys Seen In The Past Week: Green Brick, Intel, Teledyne And More   Benzinga
Jan 24, 2021
07:12AM EST  Notable Insider Buys Of The Past Week: Affirm, HEICO, Vector Group, Biotechs And More   Benzinga
Jan 22, 2021
05:41AM EST  Perceptive Advisors Reported Purchase of 1,368,421 Shares of Aldeyra Therapeutics Thursday @ Avg Price: $9.50/Share in a Form 4 Filing on Thursday   Benzinga
Jan 20, 2021
07:32AM EST  The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study   Benzinga
07:09AM EST  Aldeyra Therapeutics Announces Closing Of Underwritten Public Offering Of 7.87 Mln Shares At $9.50/shr   RTTNews
07:00AM EST  Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares   Business Wire
Jan 16, 2021
02:22PM EST  Notable Insider Buys Of The Past Week: Conagra Brands Plus Plenty Of Biotech Activity   Benzinga
Jan 14, 2021
07:57AM EST  The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates   Benzinga
05:58AM EST  Aldeyra Therapeutics Priced ~6.8M Share Public Offering of Common Stock @$9.50/Share   Benzinga
Jan 13, 2021
09:36PM EST  Aldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock   Business Wire
04:06PM EST  Aldeyra Therapeutics Announces Proposed Public Offering Of Common Stock   RTTNews
04:02PM EST  Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock; No Terms Disclosed   Benzinga
04:01PM EST  Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock   Business Wire
07:25AM EST  The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations   Benzinga
Jan 12, 2021
08:16AM EST  The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue   Benzinga
Jan 8, 2021
08:00AM EST  Aldeyra Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BioConnect 2021 Virtual Conference   Business Wire
Jan 7, 2021
10:56AM EST  Shares of Aldeyra Therapeutics, Inc. (ALDX) are climbing more than 10% Thursday morning after the company reported positive top-line results from the phase III study of its lead drug candidate Reproxalap in dry eye disease.   RTTNews
07:09AM EST  Aldeyra Therapeutics Announces Positive Top-Line Symptom and Sign Results from Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye Disease   Benzinga
07:05AM EST  Aldeyra Announces Positive Top-Line Results From Run-In Cohort Of Phase 3 TRANQUILITY Trial In Dry Eye Disease   RTTNews
07:00AM EST  Aldeyra Therapeutics Announces Positive Top-Line Symptom and Sign Results from Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye Disease   Business Wire
Jan 6, 2021
04:31PM EST  Alderyra Therapeutics To Host Conference Call, Webcast To Discuss Top-Line Symptom, Redness, Schirmer's Test Results From Run-In Cohorot Of Phase 3 TRANQULITY Trial   Benzinga
04:30PM EST  Aldeyra Therapeutics to Host Conference Call and Webcast to Discuss Top-Line Symptom, Redness, and Schirmer's Test Results from Run-in Cohort of Phase 3 TRANQUILITY Trial   Business Wire
Dec 22, 2020
08:20AM EST  Aldeyra Therapeutics Announces Confirmation Of SARS-CoV-2 Antiviral Activity Of ADX-1612   RTTNews
08:11AM EST  Aldeyra Therapeutics Announces Confirmation Of Antiviral Activity Of ADX-1612   Benzinga
Dec 17, 2020
08:09AM EST  Aldeyra Initiates Phase 2 Trials Of ADX-629 For The Treatment Of COVID-19, Atopic Asthma, And Psoriasis   RTTNews
08:02AM EST  Aldeyra Therapeutics Announces Initiation Of Phase 2 Clinical Trials Of ADX-629 Orally Administered RASP Inhibitor For Treatment Of COVID-19, Atopic Asthma, And Psoriasis   Benzinga
08:00AM EST  Aldeyra Therapeutics Announces Initiation of Phase 2 Clinical Trials of ADX-629, a First-in-Class Orally Administered RASP Inhibitor, for the Treatment of COVID-19, Atopic Asthma, and Psoriasis   Business Wire
Dec 16, 2020
11:25AM EST  Benzinga's Top Upgrades, Downgrades For December 16, 2020   Benzinga
10:24AM EST  Berenberg Initiates Coverage On Aldeyra Therapeutics with Buy Rating, Announces Price Target of $32   Benzinga
Dec 8, 2020
08:21AM EST  Aldeyra Announces Enrollment Of First Patient In Phase 3 TRANQUILITY Trial   RTTNews
08:02AM EST  Aldeyra Announces First Patient Enrolled In Phase 3 TRANQUILITY Trial Of Reproxalap For The Treatment Of Dry Eye Disease   Benzinga
Nov 13, 2020
08:00AM EST  Aldeyra Therapeutics to Participate in the Jefferies and A.G.P./Alliance Global Partners Virtual Investor Conferences   Business Wire
Nov 11, 2020
07:38AM EST  The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap   Benzinga
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Nov 5, 2020
07:16AM EST  Aldeyra Therapeutics Q3 EPS $(0.23) Beats $(0.27) Estimate   Benzinga
07:00AM EST  Aldeyra Therapeutics Announces Third-Quarter 2020 Financial Results and Provides Corporate Update   Business Wire
04:34AM EST  Earnings Scheduled For November 5, 2020   Benzinga
Nov 4, 2020
08:00AM EST  Aldeyra to Participate in the American Academy of Ophthalmology Eyecelerator 2020 Virtual Conference on Friday, November 6   Business Wire
Nov 2, 2020
08:59AM EST  Morgan Stanley Maintains Equal-Weight on Rocket Companies, Lowers Price Target to $23   Benzinga
Oct 30, 2020
09:22PM EDT  Aldeyra Has 'Catalayst-Rich' 12 Months Ahead, Jefferies Says In Bullish Initiation   Benzinga
10:06AM EDT  Benzinga's Top Upgrades, Downgrades For October 30, 2020   Benzinga
06:08AM EDT  Jefferies Initiates Coverage On Aldeyra Therapeutics with Buy Rating, Announces Price Target of $24   Benzinga
Oct 29, 2020
08:00AM EDT  Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third-Quarter 2020 Financial Results and Corporate Update   Business Wire
Oct 22, 2020
08:00AM EDT  Aldeyra to Present New Reproxalap Data from Phase 2 Clinical Trial in Allergic Conjunctivitis at American Academy of Ophthalmology 2020 Annual Meeting   Business Wire
Oct 20, 2020
08:17AM EDT  The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger   Benzinga
Oct 16, 2020
10:18AM EDT  Mid-Morning Market Update: Markets Open Higher; Schlumberger Reports Mixed Q3 Results   Benzinga
09:40AM EDT  Benzinga's Top Upgrades, Downgrades For October 16, 2020   Benzinga
06:00AM EDT  BTIG Initiates Coverage On Aldeyra Therapeutics with Buy Rating, Announces Price Target of $29   Benzinga
Sep 16, 2020
08:00AM EDT  Aldeyra to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit   Business Wire
Sep 9, 2020
08:02AM EDT  Aldeyra Receives Study May Proceed Letter From FDA To Initiate Clinical Trial Of ADX-629 In COVID-19 Patients   Benzinga
Sep 3, 2020
08:00AM EDT  Aldeyra to Participate in Citi's 15th Annual BioPharma Virtual Conference   Business Wire
Aug 11, 2020
07:09AM EDT  Citigroup Maintains Buy on Aldeyra Therapeutics, Lowers Price Target to $22   Benzinga
Aug 6, 2020
11:22AM EDT  Aldeyra Therapeutics Earlier Reported Q2 EPS $(0.25) Beats $(0.34) Estimate   Benzinga
07:01AM EDT  Aldeyra Therapeutics Announces Second-Quarter 2020 Financial Results and Provides Corporate Update   Business Wire
Aug 4, 2020
08:00AM EDT  Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences   Business Wire
Jul 30, 2020
08:00AM EDT  Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second-Quarter 2020 Financial Results and Corporate Update   Business Wire
Jul 15, 2020
04:49AM EDT  55 Biggest Movers From Yesterday   Benzinga
Jul 14, 2020
08:09AM EDT  Aldeyra Therapeutics Announces Stock Sales To Perceptive Advisors And Avidity Partners   Benzinga
Jul 13, 2020
04:05PM EDT  Aldeyra Therapeutics to Present at the OIS Virtual Public Company Showcase on July 16, 2020   Business Wire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC